PTGS2 and non-small cell lung carcinoma: Consistently, treating A549 cells with LY294002 to inhibit PI3K activity was sufficient to reduce COX-2 levels, and co-treatment with Corynoxine did not further decrease such expression, suggesting that the ability of Corynoxine to suppress malignant activities in NSCLC cells is at least partially mediated by the PI3K/AKT/COX-2 axis.